Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Targacept

- PMLiVE

New study finds brains of ‘superagers’ contain larger neurones in memory region

Superagers had 'significantly larger' brain cells in a region of the brain that is critical for memory

- PMLiVE

Biogen and Eisai’s lecanemab shows promise in confirmatory Alzheimer’s study

Results from the phase 3 trial showed reduction in clinical decline

- PMLiVE

Alzheimer’s Research UK announces ‘record’ financial performance for 2021/22

The charity was forced to put much of its activity on hold due to the COVID-19 pandemic

- PMLiVE

CuraSen Therapeutics doses first patients with novel combination therapy in dementia study

CuraSen Therapeutics doses first patients with novel combination therapy in dementia study

- PMLiVE

Alzheimer’s Research UK calls for urgent action to prioritise investment in last-stage dementia research

The number of participants recruited to late-stage dementia drug trials by the NIHR Clinical Research Network in England last year was around 100 times fewer than for cancer

- PMLiVE

Alpha Cognition announces positive results for Alzheimer’s disease treatment

The number of people with dementia is predicted to increase to around one million by 2025, increasing to 1.6 million by 2040

- PMLiVE

Alzheimer’s Research UK launches new report to understand link between sport and dementia

The charity will invest £500,000 to kick-start the action outlined in the report, including widening research into the links beyond elite sport players

- PMLiVE

COVID-19 linked to higher risk of brain fog, dementia and psychosis in new study

The study also found that adults faced an increased risk of anxiety and depression, but this subsided within two months of illness

- PMLiVE

UK government to launch national mission to tackle dementia

One million people are predicted to be living with dementia by 2025

Powering Rapid Cognitive Analysis with AI

Dr. Tom Sawyer, CFO at Cognetivity Neurosciences, discusses the benefits of AI-driven dementia detection technology for patients, health care providers, and clinical research.

Impetus Digital

- PMLiVE

Merck and Cerevance to research novel targets in Alzheimer’s disease

The total value of the deal is expected to be around $1.1bn

- PMLiVE

Merck and Cerevance to research novel targets in Alzheimer’s disease

The total value of the deal is expected to be around $1.1bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links